While there are no trials comparing targeted therapy to intensive therapy or lower-intensity treatment specifically in the post-allo-HCT relapse setting, the available data for FLT3, IDH1, and IDH2 inhibitors suggest comparable or improved response rates with decreased toxicity, making targeted therapy the treatment of choice for relapsed AML with a targetable mutation. This evidence concerns the gene IDH2 and acute myeloid leukemia.